Rani Therapeutics Holdings, Inc. Share Price & Technical Analysis
RANI · $1.07 (0.00%)
Healthcare / Biotechnology
$1.07
0.00%
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substa…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
22% return in May, -23% avg return in past 3 year May month.
7% return in 2026, 58% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -14% | 17% | -46% | 29% | 22% | – | – | – | – | – | – | – | 7% |
| 25 | 0% | 7% | -13% | -8% | -45% | -17% | 0% | 0% | 0% | 340% | -33% | -7% | 223% |
| 24 | 6% | 6% | -18% | 106% | -13% | -28% | -26% | 14% | -31% | 5% | -13% | -30% | -23% |
| 23 | -8% | 15% | -17% | -11% | -11% | 0% | 5% | -12% | -42% | -9% | 0% | 65% | -26% |
| 22 | 24% | -19% | -15% | -9% | -7% | -11% | 7% | -21% | 7% | -37% | 36% | -31% | -76% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The have a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; and Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$132.40M
P/E ratio
—
52W high
$3.87
52W low
$0.39
Volume
7,64,275
Beta
0.76
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Rani Therapeutics Holdings, Inc. share price today?
- Rani Therapeutics Holdings, Inc. (RANI) last traded around $1.07 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RANI have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RANI. Download the app for real-time alerts.
- How can I analyze Rani Therapeutics Holdings, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.